Treatment with thyroid hormone

B Biondi, L Wartofsky - Endocrine reviews, 2014 - academic.oup.com
Thyroid hormone deficiency can have important repercussions. Treatment with thyroid
hormone in replacement doses is essential in patients with hypothyroidism. In this review …

Role of the hypothalamic-pituitary-adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products

JI Webster, EM Sternberg - Journal of Endocrinology, 2004 - joe.bioscientifica.com
The present study was undertaken to investigate heat stress protein (HSP)-70 mRNA
induction and p38 MAP kinase (MAPK) activity in response to ischaemic stress in the …

MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma

L Liu, J Wang, X Li, J Ma, C Shi, H Zhu, Q Xi… - Biochemical and …, 2015 - Elsevier
Abstract microRNAs (miRNAs) are frequently dysregulated in human malignancies. It was
recently shown that miR-204-5p is downregulated in papillary thyroid carcinoma (PTC); …

Cytotoxic chemotherapy for differentiated thyroid carcinoma

SI Sherman - Clinical Oncology, 2010 - Elsevier
For patients with metastatic differentiated thyroid carcinoma that progresses despite
standard therapies, systemic cytotoxic chemotherapy has traditionally been a limited option …

ENDOCRINE TUMOURS: approach to the patient with advanced differentiated thyroid cancer

M Schlumberger, SI Sherman - European journal of …, 2012 - academic.oup.com
Patients with advanced thyroid cancer may benefit from l-thyroxine treatment at doses that
suppress serum TSH level, local treatment interventions, and radioiodine therapy. In those …

[HTML][HTML] Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells

S Bulotta, R Corradino, M Celano… - Journal of …, 2013 - jme.bioscientifica.com
The diagnosis of conventional and oncocytic poorly differentiated (oPD) thyroid carcinomas
is difficult. The aim of this study is to characterise their largely unknown miRNA expression …

[HTML][HTML] miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma

E Minna, P Romeo, L De Cecco, M Dugo, G Cassinelli… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Thyroid cancer incidence is rapidly increasing. Papillary Thyroid Carcinoma (PTC), the most
frequent hystotype, usually displays good prognosis, but no effective therapeutic options are …

Approach to the thyroid cancer patient with bone metastases

JA Wexler - The Journal of Clinical Endocrinology & Metabolism, 2011 - academic.oup.com
Thyroid cancer incidence has been increasing for de-cades in the United States (1, 2). There
are known risk factors for thyroid cancer including female gender, advancing age, family …

miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1

S Ma, W Jia, S Ni - Biochemical and biophysical research communications, 2018 - Elsevier
Background Increasing evidence has emphasized the important roles of differentially
expressed miRNAs in papillary thyroid cancer (PTC) development. miR-199a-5p was …

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib …

DS Hong, ME Cabanillas, J Wheler… - The Journal of …, 2011 - academic.oup.com
Abstract Purpose: Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET)
kinase pathways are important in thyroid cancer. We tested sorafenib, a B-Raf, RET, and …